文献速递胸部肿瘤

奥希替尼联合铂类与培美曲塞治疗初治EGFR突变晚期非鳞状非小细胞肺癌的2期研究:OPAL研究

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
PubMed 文献 · Eur J Cancer · 2023-03-02

这项多中心2期试验评估奥希替尼联合铂类化疗(OPP)在初治EGFR突变晚期非鳞状非小细胞肺癌患者中的安全性和疗效。67例患者接受奥希替尼80 mg每日一次联合顺铂(A组)或卡铂(B组)及培美曲塞500 mg/m2治疗4周期,随后奥希替尼联合培美曲塞维持治疗。全分析集客观缓解率为90.9%(95%CI 84.0-97.8),中位无进展生存期为31.0个月(95%CI 26.8个月-未达到),中位总生存期未达到。

要点

  • 全分析集客观缓解率90.9%(95%CI 84.0-97.8),疾病控制率97.0%(95%CI 92.8-100.0)。
  • 中位无进展生存期31.0个月(95%CI 26.8个月-未达到),中位总生存期未达到。
  • 未发生治疗相关死亡,35例(52.2%)患者终止方案治疗,其中10例(14.9%)因不良事件终止。

核心结论

  • 这是首个显示OPP方案在初治EGFR突变晚期非鳞状非小细胞肺癌患者中具有优异疗效且毒性可接受的研究。

研究设计与样本

  • 多中心2期试验,纳入初治EGFR突变晚期非鳞状非小细胞肺癌患者67例(A组34例,B组33例),入组时间为2019年7月至2020年2月。
  • 患者接受奥希替尼80 mg每日一次,联合顺铂75 mg/m2(A组)或卡铂(曲线下面积AUC=5;B组),加培美曲塞500 mg/m2治疗4周期,随后奥希替尼80 mg每日一次联合培美曲塞500 mg/m2每3周维持治疗。
  • 主要终点为安全性和客观缓解率,次要终点为完全缓解率、疾病控制率和无进展生存期。

主要发现

  • 截至2022年2月28日数据截止,35例(52.2%)患者终止方案治疗,其中10例(14.9%)因不良事件终止;未发生治疗相关死亡。
  • 全分析集客观缓解率为90.9%(95%CI 84.0-97.8),完全缓解率为3.0%(95%CI 0.0-7.2),疾病控制率为97.0%(95%CI 92.8-100.0)。
  • 基于更新生存数据(数据截止2022年8月31日,中位随访时间33.4个月),中位无进展生存期为31.0个月(95%CI 26.8个月-未达到),中位总生存期未达到。

关键数值与推荐

  • 客观缓解率90.9%(95%CI 84.0-97.8),完全缓解率3.0%(95%CI 0.0-7.2),疾病控制率97.0%(95%CI 92.8-100.0)。
  • 中位无进展生存期31.0个月(95%CI 26.8个月-未达到),中位总生存期未达到(数据截止2022年8月31日,中位随访时间33.4个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients received osimertinib 80 mg once daily (QD), with either cisplatin 75 mg/m2 (arm A) or carboplatin (area under the curve [AUC] = 5; arm B), plus pemetrexed 500 mg/m2 for four cycles and maintenance therapy of osimertinib 80 mg QD with pemetrexed 500 mg/m2 every 3 weeks. The primary end-points were safety and objective response rate (ORR), and the secondary end-points were complete response rate (CRR), disease control rate (DCR), and progression-free survival (PFS). RESULTS: In total, 67 patients (34 in arm A and 33 in arm B) were enrolled between July 2019 and February 2020. At the data cutoff (28th February 2022), 35 (52.2%) patients had discontinued the protocol treatment, including 10 (14.9%) due to adverse events. No treatment-related deaths occurred. In the full analysis set, the ORR, CRR, and DCR were 90.9% (95% confidence interval [CI], 84.0-97.8), 3.0% (0.0-7.2), and 97.0% (92.8-100.0), respectively. Based on updated survival data (data cutoff on August 31, 2022, median follow-up time: 33.4 months), the median PFS was 31.0 months (95% CI, 26.8 months-not reached) and median overall survival was not reached. CONCLUSIONS: This is the first study to show that OPP has excellent efficacy with acceptable toxicity in previously untreated EGFR-mutated advanced non-squamous NSCLC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. Eur J Cancer. 2023. PMID: 36966696. doi:10.1016/j.ejca.2023.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。